- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00239902
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
November 1, 2011 updated by: Novartis Pharmaceuticals
Two-year Extension of a One-year, Multicenter, Randomized, Partially-blinded Study of the Safety and Efficacy of FTY720 Combined With Corticosteroids and Full or Reduced-dose Cyclosporine, USP [Modified] (Novartis Brand) in de Novo Adult Renal Transplant Recipients
This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
Study Overview
Study Type
Interventional
Enrollment
396
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria
- Completion of Core study
Exclusion Criteria
Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Permanent resumption of dialysis within 36 months post transplant
|
Surgical removal of graft within 36 months post transplant
|
Death within 36 months post transplant
|
IA, IB, IIA, IIB or III diagnosed by biopsy according to Banff 97 criteria within 36 months post transplant
|
Discontinuation within 36 months post transplant
|
Secondary Outcome Measures
Outcome Measure |
---|
FEV1 , FVC, DLCO within 36 months post transplant
|
Serum creatinine and estimated creatinine clearance within 36 months post transplant
|
Absolute lymphocyte count within 36 months post transplant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Primary Completion (Actual)
November 1, 2004
Study Registration Dates
First Submitted
October 13, 2005
First Submitted That Met QC Criteria
October 13, 2005
First Posted (Estimate)
October 17, 2005
Study Record Updates
Last Update Posted (Estimate)
November 2, 2011
Last Update Submitted That Met QC Criteria
November 1, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CFTY720A0121E1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)Active, not recruitingKidney Transplantation | Renal Transplantation | Renal Transplant RecipientUnited States
-
Astellas Pharma Korea, Inc.CompletedKidney Transplantation | Renal Transplantation | Stable Renal RecipientsKorea, Republic of
-
University of Oslo School of PharmacyCompletedHeart Transplantation | Renal TransplantationNorway
-
NovartisCompletedOrgan Transplantation, Renal Transplantation
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ TransplantationTerminatedKidney Transplantation | Renal TransplantationUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | Renal Transplant | Renal Transplantation | Transplant Rejection | Transplant ToleranceUnited States
-
University of North Carolina, Chapel HillMallinckrodtWithdrawnKidney Transplantation | Renal Transplantation | FSGSUnited States
-
Bristol-Myers SquibbCompletedKidney Transplantation | Graft Rejection | Renal TransplantationUnited States
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceActive, not recruitingRenal TransplantationFrance
Clinical Trials on FTY720
-
University Hospital, Basel, SwitzerlandNovartisCompletedRett's SyndromeSwitzerland
-
NovartisCompletedRelapsing Multiple SclerosisGermany, Italy, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom
-
NovartisCompletedRenal InsufficiencyRussian Federation
-
Novartis PharmaceuticalsTerminatedPrimary Progressive Multiple SclerosisUnited States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
-
Novartis PharmaceuticalsCompletedKidney Transplantation
-
Tianjin Medical University General HospitalCompletedStroke | Stroke, Acute | Cerebral Stroke | Ischemic Cerebrovascular Accident | Vascular AccidentChina
-
Novartis PharmaceuticalsCompletedMultiple SclerosisItaly, Belgium, Germany
-
NovartisCompletedMultiple SclerosisSwitzerland, Germany, Spain, Portugal, Canada, Denmark, Finland, France, Italy, Poland, United Kingdom
-
NovartisCompletedAsthmaUnited Kingdom
-
Novartis PharmaceuticalsRecruiting